Venetoclax (Venclexta)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Venetoclax (Venclexta), 10 mg, 50 mg, and 100 mg oral tablets. Indication: In combination with obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia.